If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 111 - 120 of 272
A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer
Objective
This is a first-in-human study of MEN2312, a lysine acetyltransferase 6 (KAT6) inhibitor, in adult participants with advanced breast cancer.
Protocol No
STEMLINE-MEN2312-01
Categories
An Open-Label, Phase 1, Multicenter Study to Evaluate the Safety and Preliminary Anti-Tumor Activity of NT-175 in Human Leukocyte Antigen-A*02:01-Positive Adult Subjects with Unresectable, Advanced and or Metastatic Solid Tumors That Are Positive for
Objective
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/​or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Protocol No
NEOGENE-NT-175-201
Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer
Objective
Comparing Sentinel Lymph Node (SLN) Biopsy with Standard Neck Dissection for patients with early-stage oral cavity cancer.
Protocol No
NRG-HN006
Categories
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL
Objective
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
Protocol No
ALLIANCE-A041501-ALL
Categories
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa
Objective
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)
Protocol No
DERM-INCYTE-INCB018424-325
Categories
A Phase 1, Open-label Study to Evaluate the Safety and Clinical Activity of Azercabtagene Zapreleucel in Participants with B-cell Mediated Autoimmune Disorders
Objective
Azercabtagene Zapreleucel in B-cell Mediated Autoimmune Disorders
Protocol No
NEURO-TG-AZERCEL-101
Standardizing Treatments for Pulmonary Exacerbations: A Platform for Evaluating Treatment Decisions to Improve Outcomes (STOP360) Aminoglycoside Study (AG Study)
Objective
Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study (STOP360AG)
Protocol No
PULM-CFF-STOP360AG
Categories
An Open-Label, Global, Multi-Arm Study to Evaluate the Efficacy and Safety of Relacorilant in Combination with Different Treatment Regimens in Patients with Gynecological Cancers (BELLA)
Objective
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Protocol No
CORCEPT-CORT125134-557-BELLA
Categories
A Phase 1/2, First-in-Human Study of the Menin-KMT2A (MLL1) Inhibitor Bleximenib in Participants with Acute Leukemia
Objective
This project is being done to see if a safe dose of JNJ-75276617 can be identified for treating participants with acute leukemia, including acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL).
Protocol No
JNJ-75276617ALE1001
A Phase III, Open-Label, Randomised Study of Osimertinib With or Without Datopotamab Deruxtecan (Dato-DXd), as First-Line Treatment in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation-Positive, Locally Advanced or Metastatic Non-Sma
Objective
Study of first-line osimertinib with or without Dato-Dxd for EGFRm locally advanced or metastatic NS
Protocol No
AZ-D516NC00001-TROPION-LUNG14
Categories